GeoVax Labs Files 8-K: Corporate Updates
Ticker: GOVX · Form: 8-K · Filed: Sep 17, 2024 · CIK: 832489
Sentiment: neutral
Topics: corporate-filing, company-structure, financial-reporting
TL;DR
GeoVax Labs filed an 8-K on Sept 17, 2024, updating corporate info and financials.
AI Summary
GeoVax Labs, Inc. filed an 8-K on September 17, 2024, reporting other events and financial statements. The filing details the company's corporate structure, including its state of incorporation (Delaware) and fiscal year end (December 31). It also lists previous company names and dates of name changes, such as DAUPHIN TECHNOLOGY INC in 1994 and SUCCESSO INC in 1991.
Why It Matters
This filing provides essential background information on GeoVax Labs' corporate history and structure, which is relevant for understanding its current operations and any future strategic moves.
Risk Assessment
Risk Level: low — The filing is a routine corporate update and does not appear to contain significant new financial or operational risks.
Key Numbers
- 1231 — Fiscal Year End (Indicates the end of the company's financial reporting year.)
- 001-39563 — SEC File Number (Identifies the company's filing with the SEC.)
Key Players & Entities
- GeoVax Labs, Inc. (company) — Registrant
- September 17, 2024 (date) — Report Date
- Delaware (jurisdiction) — State of Incorporation
- DAUPHIN TECHNOLOGY INC (company) — Former Company Name
- SUCCESSO INC (company) — Former Company Name
FAQ
What specific 'Other Events' are detailed in this 8-K filing?
The provided text does not specify the 'Other Events' beyond stating it is an item reported in the 8-K.
What are the primary business activities of GeoVax Labs, Inc. as indicated by its SIC code?
GeoVax Labs, Inc. is classified under SIC code 2834, which corresponds to Pharmaceutical Preparations.
When did GeoVax Labs, Inc. last change its name prior to its current identity?
The company was formerly known as DAUPHIN TECHNOLOGY INC, with a name change date of October 2, 2006.
What is the physical address of GeoVax Labs, Inc.?
The company's business address is 1900 LAKE PARK DRIVE, SUITE 380, SMYRNA, GA 30080.
What is the IRS Employee Identification Number for GeoVax Labs, Inc.?
The IRS Employee Identification Number for GeoVax Labs, Inc. is 87-0455038.
Filing Stats: 530 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-09-17 16:02:22
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share GOVX The Nasdaq Capital M
Filing Documents
- govx20240916_8k.htm (8-K) — 25KB
- 0001437749-24-029372.txt ( ) — 169KB
- govx-20240917.xsd (EX-101.SCH) — 4KB
- govx-20240917_def.xml (EX-101.DEF) — 13KB
- govx-20240917_lab.xml (EX-101.LAB) — 17KB
- govx-20240917_pre.xml (EX-101.PRE) — 13KB
- govx20240916_8k_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. The Company convened a Special Meeting of Stockholders (the "Special Meeting") on September 17, 2024 and adjourned the Special Meeting without any business being conducted due to lack of the required quorum. The Company has determined to keep the polls open and reconvene the Special Meeting on October 1, 2024 at 8:30 a.m. Eastern Time to provide its stockholders additional time to vote on the proposals described in the proxy statement filed with the Securities and Exchange Commission on August 1, 2024. No changes have been made to the proposals to be voted on by stockholders at the Special Meeting. At the time the Special Meeting was adjourned, proxies had been submitted by stockholders representing approximately 24% of the shares of the Company's common stock outstanding and entitled to vote. Proxies previously submitted in respect of the Special Meeting will be voted at the reconvened Special Meeting unless properly revoked, and stockholders who have previously submitted a proxy or otherwise voted need not take any action.
Financial Statements and Exhibits
Financial Statements and Exhibits. None.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GeoVax Labs, Inc. September 17, 2024 By: /s/ Mark W. Reynolds Name: Mark W. Reynolds Title: Chief Financial Officer